Alembic-Accu-Break alliance targets dosage convenience
This article was originally published in Scrip
India's Alembic Pharmaceuticals and Accu-Break Pharmaceuticals have entered into a development and licence pact to develop new branded products based on the US firm's Accu-Break tablet technologies. The alliance is seen opening a new front in Alembic's strategy to target incremental but important innovations in areas such as drug delivery, product strength and dosage.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.